

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HealthyWay Inc.
健康之路股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2587)

INSIDE INFORMATION
POSITIVE PROFIT ALERT

This announcement is made by HealthyWay Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (the “**Year 2025**”) and other information currently available to the Board, the Group is expected to record (i) a revenue of not less than RMB1.5 billion for the Year 2025, representing an increase of not less than 25% as compared with the year ended 31 December 2024 (the “**Year 2024**”); and (ii) a profit of not less than RMB50 million for the Year 2025, as compared to a net loss of RMB269 million for the Year 2024. Such expected positive performance is primarily due to the following reasons: (i) revenue growth in content services from RMB577 million for the Year 2024 to not less than RMB800 million for the Year 2025, driven by strategic realignment according to market dynamics, such as integration of resources and new service models; (ii) revenue growth in information technology services from RMB296 million for the Year 2024 to not less than RMB350 million for the Year 2025, primarily driven by increased revenue from the Group’s big data technology services and the launch of its artificial intelligence (AI) software products. Notably, the Group’s self-developed AI software products contributed approximately RMB30 million revenue in its first year of launch in the Year 2025; and (iii) ongoing enhancements in operational efficiency. In the Year

2024, total operating expenses, including administrative expenses, selling expenses and R&D expenses, accounted for approximately 29% of the revenue. Such percentage decreased in the Year 2025 amid business expansion.

As at the date of this announcement, the Company is still in the process of finalising the Group's consolidated results for the Year 2025. The information contained in this announcement is only based on the Board's preliminary assessment with reference to the information currently available, including the unaudited consolidated management accounts of the Group for the Year 2025, which are yet to be finalised and have not been reviewed by the independent external auditors of the Company, nor reviewed by the audit committee of the Board, and therefore are subject to amendments and adjustments where necessary. The actual results of the Group for the Year 2025 may differ from the information contained in this announcement. Further details of the Group's financial results and performance will be disclosed in the Company's annual results announcement for the Year 2025, which is expected to be published by the end of March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

HealthyWay Inc.

Zhang Wanneng

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Fuzhou, the PRC, 12 February 2026

As at the date of this announcement, the Board comprises Mr. Zhang Wanneng and Mr. Chen Jing as executive directors; Mr. Zhang Xiangming as non-executive director; and Mr. Xu Jing, Dr. Lu Tao and Ms. Deng Xiaolan as independent non-executive directors.